


Company Overview



About Us

Cellaion treats patients with life-threatening liver diseases, with the double aim to save life and avoid liver transplantation.

Our Patients

Our patients suffer from **chronic liver disease**, often unnoticed. Suddenly, an acute injury leads to inflammation of the liver and the loss of its function; the patient becomes jaundiced, with a swollen abdomen filled with liquid, brain dysfunction and bleeding complications.



The liver plays a central role in the body. It purifies the blood and ensures the composition of the circulating fluids, providing vital energy to the body. When the liver fails, toxic compounds accumulate in the blood, damaging renal, cerebral, cardiac and pulmonary function, and the required nutrients and energy fail to maintain heart and brain function.

All organs are affected by the liver impairment; this is called "**Acute-on-Chronic Liver Failure**".



Hospitalized patient present with jaundice, severe ascites, denutrition and oxygen requirements (lung dysfunction)

ACLF **Acute-on-Chronic Liver Failure** is a liver deficiency leading to "**multiorgan failure**". It is Cellaion's the first target disease, using HepaStem® technology to restore liver function and heal affected organs.

Our Product HepaStem®

HepaStem® is the lead compound of Cellaion. It is a unique proprietary cell, derived from human liver tissue, and expanded at large scale in Cellaion. It is classified as an "**Advanced Therapy**" by the health authorities.

HepaStem® has 3 main mechanisms of action

1

Blocking inflammation

in the liver. HepaStem® finds its own way to the liver following simple peripheral vein infusion, where it will release compounds able to fight inflammation and modulate the immune system to stop its aggression to the liver tissue.

2

Regenerating the injured liver tissue

HepaStem® produces and releases in situ growth factors to boost the capacity of the liver to regenerate from its own cells.

3

Reinforcing the defense barrier

HepaStem® reinforces the defense of the liver by re-building its barrier against toxins and bacteria migrating from the gut.

+

Remodeling the liver

HepaStem® participates in the remodeling of the general liver composition through antifibrotic properties.

HepaStem® Clinical Development

Safety

HepaStem® has already been infused safely to more than **130 patients**.

Three completed trials have shown its perfect safety, including in children, and this safety has been acknowledged by Regulatory Authorities and Independent Experts who oversee the ongoing current clinical trial. It is easily administered to the patient, with no specific expertise required by the physicians in charge.

Efficacy

In previous trials, HepaStem® has shown preliminary signs of efficacy on jaundice, liver function and improvement of life risk scores.

This preliminary efficacy results has led to the launch of the current phase IIB, proof-of-concept trial aiming to reach registration.

HepaStem® has even been administered to children suffering from congenital diseases.

Market Approval

End of 2024

Cellaion has designed the current ongoing phase IIB trial to demonstrate the life saving capacity of HepaStem® in Acute on Chronic Liver Failure. Cellaion will seek conditional approval in Europe and fast track in US. HepaStem® is a breakthrough technology; there is no alternative treatment and more 100000 patients are affected in EU, and similarly in the USA. Cellaion plans to bring HepaStem® to the market by the **end of 2024**.

Platform Product

Pipeline

HepaStem® is a platform product.

Beside ACLF, Cellaion has completed a human safety trial for fatty liver disease (Non-Alcoholic Steato Hepatitis), the largest emerging liver disease in the world. Safety has been confirmed in severely affected patients, with cirrhosis due to NASH. Our animal data have shown the capacity of HepaStem® to improve inflammation and fibrosis in NASH animal model.

HepaStem® can also be developed in a variety of liver disorders with inflammation, and other inflammatory diseases.

